Titan Biotech has announced a 1:4 bonus share issue and an increase in authorized capital to Rs. 10.40 crore. The board also set September 29, 2026, for the 34th Annual General Meeting and confirmed a record date of September 22, 2026, for its previously recommended dividend of Rs. 0.50 per share. Investors should track future filings for the specific bonus record date.
Titan Biotech Announces 1:4 Bonus Issue and Capital Restructuring
Bonus Ratio: 1:4; Authorized Capital: Rs. 10.40 Crore
Reader Takeaway: The 1:4 bonus issue signals confidence, but investors must await the specific record date for eligibility.
What just happened
Titan Biotech Ltd's board met on September 3, 2026, to approve a bonus share issue in a 1:4 ratio. The company will issue one new share for every four held, funded by its securities premium and retained earnings, which totaled Rs. 162.58 crore as of March 2026. To support this, the board is increasing its authorized share capital from Rs. 10 crore to Rs. 10.40 crore.
Why this matters
A bonus issue is a sign of healthy liquidity and profitability. For shareholders, this increases the number of shares held without additional cost. However, the exact record date for this bonus entitlement has not yet been declared and remains a critical date for investors to watch.
AGM and Dividend Update
The 34th Annual General Meeting is set for September 29, 2026, via video conferencing. The company reaffirmed the record date for its final dividend of Rs. 0.50 per share as September 22, 2026. Share transfer books will remain closed from September 23 to September 29, 2026.
Governance
The board also proposed the re-appointment of Mr. Rohit Jain as an Independent Director for a second five-year term, effective September 30, 2026. This appointment is subject to shareholder approval during the upcoming AGM.
What to track next
Investors should monitor the company's future exchange filings for the specific record date related to the bonus issue, as this will determine the cutoff for eligibility.